Prosecution Insights
Last updated: November 20, 2026

Sahar Javanmard, USPTO Patent Examiner

Listed by the USPTO as JAVANMARD, SAHAR

Tech Center 1600 • Art Units: 1617 1622 1627

This examiner grants 65% of resolved cases

Analysis

JAVANMARD, SAHAR is a USPTO patent examiner in Tech Center 1600 and Art Unit 1617. The profile includes 756 resolved cases, an allowance rate of 65.1%, and a median of 1045 days to allowance. The interview lift is 34.0%, making interviews a meaningful consideration when planning responses and claim discussions.

The leading companies are Intra-cellular Therapies Inc., Verastem Inc., and Prilenia Neurotherapeutics Ltd. The listed firms are GOODWIN PROCTER LLP, COOLEY LLP, and HOXIE & ASSOCIATES LLC. These organizations give practitioners useful reference points for reviewing prosecution approaches in the relevant life sciences activity.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

65.1%
Allow Rate
+5.1% vs TC avg
803
Total Applications
+34.0%
Interview Lift
1045
Avg Prosecution Days
Based on 756 resolved cases, 2023–2026

Rejection Statute Breakdown

1.2%
§101 Eligibility
14.6%
§102 Novelty
46.7%
§103 Obviousness
16.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18773675 OINTMENT CONTAINING AN OXAZOLE COMPOUND Non-Final OA OTSUKA PHARMACEUTICAL CO., LTD.
18506916 aPKC INHIBITORS AND METHODS OF TREATING A NEURODEGENERATIVE DISEASE OR DISORDER Non-Final OA THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
18722917 CRYSTAL OF SUBSTITUTED PIPERIDINE COMPOUND, SALTS OF SUBSTITUTED PIPERIDINE COMPOUND, AND CRYSTALS THEREOF Non-Final OA Eisai R&D Management Co., Ltd.
18719710 NOVEL SALT OF 1-SULFONYL PYRROLE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME Non-Final OA ILDONG PHARMACEUTICAL CO., LTD.
18411512 THERAPEUTIC AGENTS FOR NEURODEGENERATIVE DISEASES Non-Final OA INTRABIO LIMITED

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Sahar Javanmard's allowance rate?

65.1% of resolved applications examined by Sahar Javanmard were allowed (756 resolved cases), compared with 34.2% across Art Unit 1617 over the last five years.

Does an interview help with examiner Sahar Javanmard?

This examiner's interview lift is +34.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Sahar Javanmard take to allow a patent?

Applications allowed by Sahar Javanmard took 1,045 days on average from filing to allowance.

Which art unit does examiner Sahar Javanmard work in?

Sahar Javanmard examines applications in Art Unit 1617 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month